Lymphoma, B Cell
6
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
17%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
DepoCyt for Active Lymphomatous or Leukemic Meningitis
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma